DOCSLIB.ORG

Gorgonenes and Further Bioactive Secondary Metabolites Derived from Marine and Terrestrial Bacteria

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gorgonenes and Further Bioactive Secondary Metabolites Derived from Marine and Terrestrial Bacteria Unusual Sesquiterpenes: Gorgonenes and Further Bioactive Secondary Metabolites Derived from Marine and Terrestrial Bacteria Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultäten der Georg-August-Universität zu Göttingen vorgelegt von Md. Hafizur Rahman aus Satkhira, Bangladesh Göttingen 2008 Referent: Prof. Dr. Hartmut Laatsch Korreferent: Prof. Dr. A. Zeeck Tag der mündlichen Prüfung: 29. Oktober 2008 Die vorliegende Dissertation wurde im Institut für Organische und Biomolekulare Chemie der Universität Göttingen in der Zeit vom August 2004 bis Oktober 2008 un- ter der Leitung von Herrn Prof. Dr. Hartmut Laatsch durchgeführt. Dedicated to my beloved parents Md Fazlur Rahman and Mrs. Fazilatunnessa Contents I Contents 1 Introduction....................................................................................................... 1 1.1 History of the use of natural products for medical applications..........................2 1.2 Approaches for the search of new natural products ............................................4 1.3 Antibiotic screening.............................................................................................6 1.4 Natural Products from Marine Bacteria...............................................................6 1.5 Therapeutic areas influenced by natural products ...............................................9 1.6 Natural products against infectious diseases; bacterial pathogens ......................9 1.7 Antifungal compounds from natural sources.....................................................10 1.8 Antibacterial compounds from natural sources .................................................11 1.9 Potential antiparasitic drugs originated from natural products..........................13 1.10 Marine derived anticancer drugs .......................................................................14 1.11 Antiviral compounds from natural sources .......................................................15 1.12 Sequiterpenes from marine microorganism.......................................................17 2 Objectives of the present investigation........................................................... 18 3 General techniques.......................................................................................... 20 3.1 Collection of strains...........................................................................................20 3.2 Pre-screening .....................................................................................................20 3.3 Chemical screening............................................................................................20 3.4 Pharmacological and biological assays .............................................................22 3.5 Cultivation and scale-up ....................................................................................22 3.6 Isolation methods...............................................................................................23 3.7 Partial identification and dereplication..............................................................23 3.8 Description of Strain Codes...............................................................................25 4 Investigation of selected marine and terrestrial Streptomycetes..................... 25 4.1 Terrestrial Streptomyces sp. ADM 14 ...............................................................25 4.1.1 1-Hydroxy-4-methoxynaphthalene-2-caboxylic acid........................................27 4.1.2 5'-Methyl-thioadenosine ....................................................................................28 4.1.3 5,7,9,11-Tetrahydroxy-4,6,8,10-tetramethyl-tridec-2-enoic acid......................30 4.2 Streptomyces sp. B7880.....................................................................................33 4.2.1 ζ-Pyrromycinone; Galirubinone C.....................................................................33 4.2.2 Cinerubin B; Ryemycin B .................................................................................35 II Contents 4.2.3 Cinerubin A/ Spartanamicin B ..........................................................................37 4.2.4 Cinerubin X.......................................................................................................38 4.3 Terrestrial Streptomyces sp. ACT 7619.............................................................39 4.3.1 Dinactin .............................................................................................................40 4.3.2 Bonactin.............................................................................................................41 4.3.3 4,10-Dihydroxy-10-methyl-dodec-2-en-1,4-olide.............................................42 4.4 Terrestrial Streptomycete GW 6311..................................................................43 4.4.1 β-Indomycinone.................................................................................................43 4.4.2 Saptomycin A....................................................................................................44 4.5 Terrestrial Streptomyces sp. GT 2005/079 ........................................................45 4.5.1 N-(7-Hydroxy-6-methyl-octyl)-acetamide ........................................................48 4.5.2 N-(7-Hydroxy-octyl)-acetamide ........................................................................50 4.5.3 N-(6-Hydroxy-6-methyl-heptyl)-acetamide ......................................................53 4.5.4 Homononactic acid amide .................................................................................56 4.5.5 2-Phenylbenzoxazole-4-carboxylic acid............................................................59 4.5.6 2-(3-Chloro-2-hydroxy phenyl) benzoxazole-4-carbxylic acid.........................61 4.6 Terrestrial Actinomycete N 435 ........................................................................63 4.6.1 Cyclo(dehydroalanyl-isoleucyl).........................................................................64 4.6.2 Cis-Cyclo(leucyl-tyrosyl) ..................................................................................65 4.6.3 Ramthacin B......................................................................................................69 4.7 Streptomyces sp. B7857.....................................................................................71 4.7.1 Bacteriogorgonene A.........................................................................................73 4.7.2 Bacteriogorgonene B.........................................................................................78 4.7.3 Bacteriogorgonene C.........................................................................................81 4.8 Terrestrial Streptomycete GW5127..................................................................84 4.8.1 13-Deoxy-1,3-dihydrodaunomycinone..............................................................85 4.8.2 4-Acetyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one..........................................87 4.8.3 N-[2-(3-Hydroxy-4-methoxy-phenyl)-ethyl]-acetamide ...................................90 4.8.4 4-(2-Hydroxyethyl)-2-methoxy-phenol.............................................................92 4.8.5 β-Rubromycin....................................................................................................93 Contents III 4.8.6 γ-Rubromycin ....................................................................................................95 4.9 Terrestrial Streptomyces sp. GW 18/1811.........................................................96 4.9.1 Komodoquinone B.............................................................................................97 4.9.2 Feudomycinone C..............................................................................................98 4.9.3 α-Hydroxyacetovanillone ..................................................................................99 4.9.4 N-Acetylhomocysteine thiolactone..................................................................103 4.9.5 Lysolipin I........................................................................................................105 5 Fungal metabolites ........................................................................................ 107 5.1 Bikaverin .........................................................................................................107 6 Plant Metabolites from Tephrosia sp............................................................ 110 6.1 Spinoflavanone B............................................................................................110 6.2 Caliphione A....................................................................................................113 6.3 Tephcalostan....................................................................................................117 6.4 Tephcalostan A................................................................................................118 6.5 Tephcalostan B and C......................................................................................121 6.6 Milletone..........................................................................................................124 6.7 Glabranine .......................................................................................................127 6.8 Betulinic acid and Betulinic acid methyl ester ................................................129 6.9 Stigmasterol and γ-Sitosterol...........................................................................131
Load more

Recommended publications
  • Topical and Systemic Antifungal Therapy for Chronic Rhinosinusitis (Protocol)
    CORE Metadata, citation and similar papers at core.ac.uk Provided by University of East Anglia digital repository Cochrane Database of Systematic Reviews Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Head K, Sacks PL, Chong LY, Hopkins C, Philpott C Head K, Sacks PL, Chong LY, Hopkins C, Philpott C. Topical and systemic antifungal therapy for chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012453. DOI: 10.1002/14651858.CD012453. www.cochranelibrary.com Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 3 METHODS ...................................... 3 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 10 CONTRIBUTIONSOFAUTHORS . 25 DECLARATIONSOFINTEREST . 26 SOURCESOFSUPPORT . 26 NOTES........................................ 26 Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) i Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Topical and systemic antifungal therapy for chronic rhinosinusitis Karen Head1, Peta-Lee Sacks2, Lee Yee Chong1, Claire Hopkins3, Carl Philpott4 1UK Cochrane Centre,
    [Show full text]
  • THE INFLUENCE of SOME ANTIFUNGAL ANTIBIOTICS on NEUROMUSCULAR TRANSMISSION B.L
    THE INFLUENCE OF SOME ANTIFUNGAL ANTIBIOTICS ON NEUROMUSCULAR TRANSMISSION B.l M. SIRSI Pharmacology Laboratory, Indian Institute of Science, Bangalore, 12. (Received January 25, 1963) The influcncc of the polyene antifungal antibiotics pimaricin, amphotericin A and B and nystatin, on neuromuscular transmission has been studied. In presence of these antibiotics both direct and indirect electrical stimulation is found. to cause varying degrees of contracture and diminished excitability of the musculature. This is in contrast to the effect of Hamycin, another polyene antibiotic which produces loss of excitability without any initial contracture of the diaphragm. Certain antibiotics have been shown to produce neuromuscular block, both in experimental animals and in humaps. Intraperitoneal administra- tion of neomycin has been followed by respiratory insufficiency or apnoea; streptomycin has caused neuromuscular block in experimental animals and in interccstal nerve preparations of human and is strongly incriminated in causing the muscular weakness and visual difficulty as also post-operative paralysis by neuromuscular blockage (Fisk, 1961, Bush, 1961). Polymyxin B is also reported to exhibit blocking action on the muscle end plate (Sabawala and Dillon, 1959). The following communication deals with the effect of certain antifungal antibiotics on the neuromuscular junction as studied by the rat phrenic nerve diaphragm preparations. METHODS The antibiotics studied were, pimaricin, amphotericin A and B, and nystatin. Their effects have been compared with those of hamycin reported earlier (Sirsi, 1963). -- The required concentrations of the antibiotics were prepared in propylene glycol and further dilutions in water. Phrenic nerve diaphragm preparations were made as described by Bulbring (1916) and were suspended in abath of 75 ml of aerated Tyrode's solution which contained twice the amount of glucose as stated in original M.
    [Show full text]
  • 1.Development and Validation Of
    International Journal Of Advanced Research In Medical & Pharmaceutical Sciences (IJARMPS-ISSN-2455-6998) Volume.4,Issue.12,December.2019 DEVELOPMENT AND VALIDATION OF KETOCONAZOLE BY RP-HPLC MOODU BALU*,Dr. SANJEEV KUMAR SUBUDHI,SHAIK ZUBAIR, S. NAVYA, RUHEENA NAAZ, SIRIMALLA.MOUNIKA. Department of Pharmaceutical Analysis, Talla padmavathi pharmacy college , urus, kareemabad, warangal,506002. ABSTRACT : The objective of the present research work was to develop a innovative, simple, and economic method for estimation of Ketoconazole in bulk and dosage form by RP-HPLC.The chromatographic conditions were performed on Phenomenex Luna C18, 100A, 5µm, 250mmx4.6mm i.d.as stationary phase and mobile phase was prepared with a mixture of Acetonitrile : 0.2% triethylamine (pH-6.5) = 70:30 (pH-6.5) flow 1.0 ml/min, with Injection Volume 10µl, at detection wavelength 243 nm and run time at 5.0 min.The analytical method is valid for estimation of Ketoconazole over a range of 10µg/ml–50 µg/ml. The results of system suitability test, linearity, precision and accuracy, robustness, specificity, LOD and LOQ and stabilities presented in this report are within the acceptance range.A specific, sensitive, economic method estimation of Ketoconazole has been developed based on ICH Guidelines with bulk and dosage forms. Key Words: Ketoconazole , HPLC, Method Development, ICH, Validation, Accuracy, Precision. I.INTRODUCTION Ketoconazole is a lipophilic imidazole derivative appears as white to off white crystalline powder. The drug is not miscible in water, miscible in strong bases and soluble to a low extent in strong acid, having molecular weight of 531.44. It is a feeble base, having acid dissociation constant values of 6.51 and 2.94, it contains five- membered azole ring emboding two nitrogen atoms.[1-4] It is a chiral drug containing a racemic (1:1) mixture of enantiomers of the cis configuration.
    [Show full text]
  • Protective Effects of Berberis Crataegina DC. (Ranunculales: Berberidaceae) Extract on Bleomycin-Induced Toxicity in Fruit Flies (Diptera: Drosophilidae)
    Revista de la Sociedad Entomológica Argentina ISSN: 0373-5680 ISSN: 1851-7471 [email protected] Sociedad Entomológica Argentina Argentina Protective effects of Berberis crataegina DC. (Ranunculales: Berberidaceae) extract on Bleomycin-induced toxicity in fruit flies (Diptera: Drosophilidae) ATICI, Tuğba; ALTUN ÇOLAK, Deniz; ERSÖZ, Çağla Protective effects of Berberis crataegina DC. (Ranunculales: Berberidaceae) extract on Bleomycin-induced toxicity in fruit flies (Diptera: Drosophilidae) Revista de la Sociedad Entomológica Argentina, vol. 77, no. 4, 2018 Sociedad Entomológica Argentina, Argentina Available in: https://www.redalyc.org/articulo.oa?id=322055706003 PDF generated from XML JATS4R by Redalyc Project academic non-profit, developed under the open access initiative Artículos Protective effects of Berberis crataegina DC. (Ranunculales: Berberidaceae) extract on Bleomycin-induced toxicity in fruit flies (Diptera: Drosophilidae) Efectos protectores de extracto de Berberis crataegina DC. (Ranunculales: Berberidaceae) frente a toxicidad inducida con Bleomicina en moscas de la fruta (Diptera: Drosophilidae) Tuğba ATICI Institute of Natural and Applied Science, Erzincan Binali Yıldırım University, Turquía Deniz ALTUN ÇOLAK [email protected] Faculty of Art and Science, Erzincan Binali Yıldırım University, Turquía Çağla ERSÖZ Revista de la Sociedad Entomológica Institute of Natural and Applied Science, Erzincan Binali Yıldırım Argentina, vol. 77, no. 4, 2018 University, Turquía Sociedad Entomológica Argentina, Argentina Received: 02 October 2018 Accepted: 06 December 2018 Published: 27 December 2018 Abstract: Antineoplastic agents due to their cytotoxic effects increase the amount of free radical in cells causing cell death. e aims of this study were to assess the possible Redalyc: https://www.redalyc.org/ toxic effects of Bleomycin (BLM) on the number of offspring and survival rate of fruit articulo.oa?id=322055706003 flies as well as the protective role of Berberis crataegina DC.
    [Show full text]
  • Colonization of Lettuce Rhizosphere and Roots by Tagged Streptomyces
    PhD School of Chemistry, Biochemistry and Ecology of Pesticide (CBEA) DOCTORAL DISSERTATION Tagging biocontrol Streptomyces to study lettuce colonization Xiaoyulong Chen To be presented with the permission of the examining board, 28th cycle of the CBEA PhD school, for public examination at Aula Magna C03 (Room C03), Faculty of Agricultural and food sciences, University of Milan, on 17.12.2015. Cover figure: Colonization of lettuce root by Streptomyces cyaneus ZEA17I, examined by confocal laser scanning microscopy. Supervisor: Professor Paolo Cortesi Department of Food, Environmental, and Nutritional Sciences University of Milan, Italy Co-supervisor: Professor Marco Saracchi Department of Food, Environmental, and Nutritional Sciences University of Milan, Italy Coordinator: Professor Daniele Daffonchio Department of Food, Environmental, and Nutritional Sciences University of Milan, Italy Examination board (ordered by first letter of the family name): 1. Professor Paolo Bertolini Department of Agricultural Sciences University of Bologna, Italy 2. Dr. Jonas Bengtsson Department of Zoology Stockholm University, Sweden 3. Professor Daniele Daffonchio Department of Food, Environmental, and Nutritional Sciences University of Milan, Italy 4. Professor George Tsiamis Dep. of Environmental and Nutritional Resources Management University of Patras, Greece 5. Dr. Laura Polito Institute of Molecular Science and Technology, CNR, Italy Contents List of original publications......................................................................................................
    [Show full text]
  • Biosynthesis and Engineering of Cyclomarin and Cyclomarazine: Prenylated, Non-Ribosomal Cyclic Peptides of Marine Actinobacterial Origin
    UC San Diego Research Theses and Dissertations Title Biosynthesis and Engineering of Cyclomarin and Cyclomarazine: Prenylated, Non-Ribosomal Cyclic Peptides of Marine Actinobacterial Origin Permalink https://escholarship.org/uc/item/21b965z8 Author Schultz, Andrew W. Publication Date 2010 Peer reviewed eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA, SAN DIEGO Biosynthesis and Engineering of Cyclomarin and Cyclomarazine: Prenylated, Non-Ribosomal Cyclic Peptides of Marine Actinobacterial Origin A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Oceanography by Andrew William Schultz Committee in charge: Professor Bradley Moore, Chair Professor Eric Allen Professor Pieter Dorrestein Professor William Fenical Professor William Gerwick 2010 Copyright Andrew William Schultz, 2010 All rights reserved. The Dissertation of Andrew William Schultz is approved, and it is acceptable in quality and form for publication on microfilm and electronically: ________________________________________________________________ ________________________________________________________________ ________________________________________________________________ Chair University of California, San Diego 2010 iii DEDICATION To my wife Elizabeth and our son Orion and To my parents Dale and Mary Thank you for your never ending love and support iv TABLE OF CONTENTS Signature Page ....................................................................................................
    [Show full text]
  • Enhancement of Bleomycin Production in Streptomyces Verticillus Through Global Metabolic Regulation of N-Acetylglucosamine and A
    Chen et al. Microb Cell Fact (2020) 19:32 https://doi.org/10.1186/s12934-020-01301-8 Microbial Cell Factories RESEARCH Open Access Enhancement of bleomycin production in Streptomyces verticillus through global metabolic regulation of N-acetylglucosamine and assisted metabolic profling analysis Hong Chen1,2†, Jiaqi Cui1,2†, Pan Wang1,2, Xin Wang1,2 and Jianping Wen1,2* Abstract Background: Bleomycin is a broad-spectrum glycopeptide antitumor antibiotic produced by Streptomyces verticil- lus. Clinically, the mixture of bleomycin A2 and bleomycin B2 is widely used in combination with other drugs for the treatment of various cancers. As a secondary metabolite, the biosynthesis of bleomycin is precisely controlled by the complex extra-/intracellular regulation mechanisms, it is imperative to investigate the global metabolic and regula- tory system involved in bleomycin biosynthesis for increasing bleomycin production. Results: N-acetylglucosamine (GlcNAc), the vital signaling molecule controlling the onset of development and antibiotic synthesis in Streptomyces, was found to increase the yields of bleomycins signifcantly in chemically defned medium. To mine the gene information relevant to GlcNAc metabolism, the DNA sequences of dasR-dasA-dasBCD- nagB and nagKA in S. verticillus were determined by chromosome walking. From the results of Real time fuorescence quantitative PCR (RT-qPCR) and electrophoretic mobility shift assays (EMSAs), the repression of the expression of nagB and nagKA by the global regulator DasR was released under induction with GlcNAc. The relief of blmT expres- sion repression by BlmR was the main reason for increased bleomycin production. DasR, however, could not directly afect the expression of the pathway-specifc repressor BlmR in the bleomycins gene cluster.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,767,552 B2 Narang (45) Date of Patent: Jul
    USOO6767552B2 (12) United States Patent (10) Patent No.: US 6,767,552 B2 Narang (45) Date of Patent: Jul. 27, 2004 (54) ADHESIVE TREATMENT FOR ORAL 5.530,037 A 6/1996 McDonnell et al. FUNGAL INFECTION 5,554,365 A 9/1996 Byram et al. 5,575.997 A 11/1996 Leung et al. (75) Inventor: Upvan Narang, Raleigh, NC (US) 5,580,565 A 12/1996 Tighe et al. 5,582,834 A 12/1996 Leung et al. (73) Assignee: Closure Medical Corporation, 5,613,942 A 3/1997 Lucast et al. Raleigh, NC (US) 5,624,669 A 4/1997 Leung et al. 9, 5,653,769 A 8/1997 Barley, Jr. et al. 5,661,170 A 8/1997 Chodosh (*) Notice: Subject to any disclaimer, the term of this 5,665,817 A 810: E. al. patent is extended or adjusted under 35 5,684,042 A 11/1997 Greff et al. U.S.C. 154(b) by 359 days. 5,716,607 A 2/1998 Byram et al. 5,717.005 A 2/1998 Richardson (21) Appl. No.: 09/898,092 5,725,491 A 3/1998 Tipton et al. 5,730,994. A 3/1998 Askill et al. (22) Filed: Jul. 5, 2001 5,753,699 A 5/1998 Greff et al. 5,755,680 A 5/1998 Ghodsian (65) Prior Publication Data 5,762.919 A 6/1998 Greff et al. 5,762.955 A 6/1998 Smith US 2003/0007947 A1 Jan. 9, 2003 5,783,177 A 7/1998 Greff et al.
    [Show full text]
  • 296 Results and Discussion. the Clinical Presentation of Cutaneous
    Results and discussion. The clinical presentation of cutaneous candidiasis can vary depending on the type of infection and the degree of immunosuppression. Most ofen, a pruritic red rash develops. Physical examination reveals a rash that begins with vesiculopustules that enlarge and rupture, causing maceration and fissuring. The area involved has a scalloped border with a white rim consisting of necrotic epidermis that surrounds the erythematous macerated base. Paronychia and onychomycosis are frequently associated with immersion of the hands in water and with diabetes mellitus. Most localized cutaneous candidiasis infections may be treated of topical antifungal agents. In cases of extensive cutaneous infections, infections in immunocompromised patients, folliculitis, or onychomycosis, systemic antifungal therapy is recommended. Topical antifungal agents include polyene antibiotics: amphotericin B, nystatin, hamycin, natamycin; azoles: bifonazole, clotrimazole, econazole, ketoconazole, miconazole, oxiconazole, sertaconazole; allylamines, for examples, terbinafine; other topical agents: undecyclinic acid, ciclopirox and etc. Systemic antifungal drugs include allylamines (terbinafine), polyene antibiotics (amphotericin B, nystatin, levorin), pyrimidine antibiotics (flucytosine). Of the clinically employed azole antifungals, only a handful are used systemically. These include ketoconazole, itraconazole, fluconazole and etc. Conclusion. Thus, we studied and analyzed modern standards of medical care for patients with cutaneous candidiasis, according to which the treatment of cutaneous candidiasis includes the use of local and systemic antifungal drugs. CURRENT TRENDS IN THE USE OF 1, 4-BENZODIAZEPINE DERIVATIVES IN MEDICAL PRACTICE Botsula I.V. Scientific supervisor: Kireyev I.V. National University of Pharmacy, Kharkiv, Ukraine [email protected] Introduction. Despite the fact that anxiety is a normal reaction of the body to the action of environmental factors, yet with chronic manifestations, it can significantly impair the quality of life.
    [Show full text]
  • Exploring the Potential of Antibiotic Production from Rare Actinobacteria by Whole-Genome Sequencing and Guided MS/MS Analysis
    fmicb-11-01540 July 27, 2020 Time: 14:51 # 1 ORIGINAL RESEARCH published: 15 July 2020 doi: 10.3389/fmicb.2020.01540 Exploring the Potential of Antibiotic Production From Rare Actinobacteria by Whole-Genome Sequencing and Guided MS/MS Analysis Dini Hu1,2, Chenghang Sun3, Tao Jin4, Guangyi Fan4, Kai Meng Mok2, Kai Li1* and Simon Ming-Yuen Lee5* 1 School of Ecology and Nature Conservation, Beijing Forestry University, Beijing, China, 2 Department of Civil and Environmental Engineering, Faculty of Science and Technology, University of Macau, Macau, China, 3 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 4 Beijing Genomics Institute, Shenzhen, China, 5 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China Actinobacteria are well recognized for their production of structurally diverse bioactive Edited by: secondary metabolites, but the rare actinobacterial genera have been underexploited Sukhwan Yoon, for such potential. To search for new sources of active compounds, an experiment Korea Advanced Institute of Science combining genomic analysis and tandem mass spectrometry (MS/MS) screening and Technology, South Korea was designed to isolate and characterize actinobacterial strains from a mangrove Reviewed by: Hui Li, environment in Macau. Fourteen actinobacterial strains were isolated from the collected Jinan University, China samples. Partial 16S sequences indicated that they were from six genera, including Baogang Zhang, China University of Geosciences, Brevibacterium, Curtobacterium, Kineococcus, Micromonospora, Mycobacterium, and China Streptomyces. The isolate sp.01 showing 99.28% sequence similarity with a reference *Correspondence: rare actinobacterial species Micromonospora aurantiaca ATCC 27029T was selected for Kai Li whole genome sequencing.
    [Show full text]
  • A Decade of Antifungal Leads from Natural Products: 2010–2019
    pharmaceuticals Review A Decade of Antifungal Leads from Natural Products: 2010–2019 Mohammed Aldholmi 1,2 , Pascal Marchand 3 , Isabelle Ourliac-Garnier 3 , Patrice Le Pape 3 and A. Ganesan 2,* 1 Department of Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia; [email protected] 2 School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK 3 Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000 Nantes, France; [email protected] (P.M.); [email protected] (I.O.-G.); [email protected] (P.L.P.) * Correspondence: [email protected] Received: 29 November 2019; Accepted: 10 December 2019; Published: 12 December 2019 Abstract: In this review, we discuss novel natural products discovered within the last decade that are reported to have antifungal activity against pathogenic species. Nearly a hundred natural products were identified that originate from bacteria, algae, fungi, sponges, and plants. Fungi were the most prolific source of antifungal compounds discovered during the period of review. The structural diversity of these antifungal leads encompasses all the major classes of natural products including polyketides, shikimate metabolites, terpenoids, alkaloids, and peptides. Keywords: fungal pathogens; antifungal agents; natural products 1. Introduction The global increase in antimicrobial resistance among pathogenic bacteria, viruses, fungi, and parasites is a serious concern for human healthcare. In the case of fungi, more than one billion individuals worldwide are affected by fungal infections and the associated mortality, over 1.5 million deaths each year, is equivalent to that caused by tuberculosis and more than triple that of malaria [1].
    [Show full text]
  • Antifungal Drugs
    PHARMACOLOGY Antimicrobial Agents: Antifungal & Antiviral Drugs Dr. Uma Tekur Professor & Head Dept. of Pharmacology Maulana Azad Medical College New Delhi – 110002 (7-8-2007) CONTENTS Antifungal Drugs Amphotericin B Flucytosine Griseofulvin Azoles Nystatin Antiviral Drugs Antiherpese virus agents Other Antiviral Drugs Immunomodulators Antiretroviral Drugs Human Immune deficiency virus 1 Antifungal Drugs Fungal infections seen in human can be : a) Superficial fungal infections of skin, hair, nail, mucous membrane. These are due to: i) Dermatomycoses which causes ring worm or tinea infestation. These dermatophytes are Epidermophyton, Microsporum and Trichophyton, and are classified according to their site of infestation e.g.; Tinea Capitis (Scalp infection), TInea corporis (body infection), Tinea barbae (infection in the beard), Tinea cruris (infection in groin), Tinea pedis (also called athlete’s foot), TInea manum (infection in hands) and Tinea unguium (infection in the hairs). ii) Candidiasis (or often referred to as thrush) or infection caused by Candida spp affects chiefly the skin, oropharynx and vagina. Seen commonly in immune compromised patients e.g., in patients of AIDS, or with HIV infections, following the use of AMA’s over prolonged periods, and in patients of diabetes mellitus. iii) Pityrosporoum orbiculare causing Ptyriasis versicolor or Tinea versicolor. This is characterized by hyperpigmented macules, which are distinct with fine scaling. Commonly seen on the face, proximal extremities and in the oropharynx. iv) Sporothrix infection of cutaneous region seen as granulomatous lesion. These spread to distant region via the lymphatic system. b) Systemic fungal infection affecting deeper tissues and organs. These include the respiratory tract infection with candidiasis, cryptococcal meningitis and endocarditis, histoplasmosis infection common in the respiratory tract, coccidiomycosis, paracoccidiomycosis, pneumocystis carinii pneumonia all affecting the respiratory system.
    [Show full text]